All Updates

All Updates

icon
Filter
Funding
HotSpot Therapeutics raises USD 100 million oversubscribed Series C
AI Drug Discovery
Nov 29, 2021
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Nov 29, 2021

HotSpot Therapeutics raises USD 100 million oversubscribed Series C

Funding

  • Massachusetts-based biotechnology company HotSpot Therapeutics has raised USD 100 million in an oversubscribed Series C funding round led by Pivotal BioVenture Partners. New investors, including Revelation Partners and Pavilion Capital, as well as existing investors Atlas Venture and Sofinnova Partners, also participated in the round. 

  • The funds will be directed toward further developing the company’s platform Smart Allostery, which entails a broad range of AI-enabled technologies, along with a hotspot-specific chemical library. The company also intends to use the funds to advance its pipeline and plans to begin clinical trials for one of its lung cancer-related products next year.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.